Business

Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE

articleRoivant Sciences Ltd.June 15, 20223/company/roivant-sciences-ltd/news/roivant-sciences-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

About this update from Roivant Sciences Ltd.

[{"type":"text","content":"Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Tuesday, June 28, 2022 to report its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provide a corporate update. To access the live conference call, please dial +1-844-224-1923 (domestic) or +1-214-989-7105 (international) and use conference ID 1036178. A webcast of the call will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call. About Roivant SciencesRoivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com. Roivant Sciences Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the \"Securities Act\"), and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), which are usually identified by the use of words such as \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intends,\" \"may,\" \"might,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"would\" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the S...

More updates from Roivant Sciences Ltd.